Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals.

NAFLD NASH hepatic steatosis nonalcoholic fatty liver disease triglyceride-glucose index

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
09 May 2022
Historique:
received: 12 04 2022
revised: 05 05 2022
accepted: 06 05 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 15 5 2022
Statut: epublish

Résumé

Insulin resistance (IR) is a major contributor to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The triglyceride-glucose (TyG) index has recently gained popularity for the assessment of IR and NAFLD due to its ease of acquisition and calculation. Therefore, we conducted this systematic review and meta-analysis to summarize the existing studies in the literature and provide a quantitative assessment of the significance of the TyG index in predicting the incidence of NAFLD. A comprehensive literature search in PubMed, EMBASE, and Web of Science databases from inception until 25 March 2022 was conducted. Published observational studies that evaluated the association between TyG index and NAFLD among the adult population and reported the hazard ratio (HR) or odds ratio (OR) for this association after multivariate analysis were included. The random-effects model was used as the primary statistical analysis model in the estimation of pooled ORs and HRs with the corresponding confidence intervals (CIs). A total of 17 observational studies, including 121,975 participants, were included. For studies analyzing the TyG index as a categorical variable, both pooled OR (6.00, CI 4.12-8.74) and HR (1.70, CI 1.28-2.27) were significant for the association between TyG index and incident NAFLD. For studies analyzing the TyG index as a continuous variable, pooled OR (2.25, CI 1.66-3.04) showed similar results. Consistent results were obtained in subgroup analyses according to the study design, sample size, ethnicity, and diabetic status. In conclusion, our meta-analysis demonstrates that a higher TyG index is associated with higher odds of NAFLD. TyG index may serve as an independent predictive tool to screen patients at high risk of NAFLD in clinical practice, especially in primary care settings. Patients with a high TyG index should be referred for a liver ultrasound and start intense lifestyle modifications. However, further large-scale prospective cohort studies are necessary to validate our findings.

Identifiants

pubmed: 35566790
pii: jcm11092666
doi: 10.3390/jcm11092666
pmc: PMC9102411
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Endocrinol Metab (Seoul). 2019 Jun;34(2):179-186
pubmed: 31257745
Arch Med Res. 2016 Jul;47(5):382-387
pubmed: 27751372
Lipids Health Dis. 2017 Jan 19;16(1):15
pubmed: 28103934
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Int J Endocrinol. 2020 Mar 10;2020:4678526
pubmed: 32256572
Clin Nutr ESPEN. 2021 Aug;44:483-487
pubmed: 34330512
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51
pubmed: 20484475
Metab Syndr Relat Disord. 2021 Apr;19(3):167-173
pubmed: 33259744
Diabetes Care. 2000 Jan;23(1):57-63
pubmed: 10857969
BMC Nephrol. 2020 Feb 17;21(1):50
pubmed: 32066395
Rom J Morphol Embryol. 2021 Apr-Jun;62(2):475-480
pubmed: 35024735
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):272-277
pubmed: 30641711
J Clin Transl Hepatol. 2019 Dec 28;7(4):362-370
pubmed: 31915606
Int J Obes (Lond). 2017 May;41(5):789-792
pubmed: 28104918
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Int J Environ Res Public Health. 2021 Jan 20;18(3):
pubmed: 33498329
J Diabetes Metab Disord. 2022 Jan 11;21(1):97-107
pubmed: 35673435
Korean J Intern Med. 2018 Jan;33(1):64-74
pubmed: 29202557
Nat Rev Gastroenterol Hepatol. 2020 Jul;17(7):377-379
pubmed: 32514153
Lipids Health Dis. 2018 Nov 20;17(1):262
pubmed: 30458848
J Clin Endocrinol Metab. 2006 Dec;91(12):4753-61
pubmed: 16968800
Lipids Health Dis. 2021 Oct 10;20(1):132
pubmed: 34629056
Lipids Health Dis. 2021 Oct 10;20(1):134
pubmed: 34629059
Syst Rev. 2021 Mar 29;10(1):89
pubmed: 33781348
Nutr Metab Cardiovasc Dis. 2022 Mar;32(3):596-604
pubmed: 35090800
Ann Hepatol. 2016 Sep-Oct;15(5):715-20
pubmed: 27493110
J Clin Transl Hepatol. 2020 Mar 28;8(1):76-86
pubmed: 32274348
Can J Gastroenterol Hepatol. 2019 Oct 7;2019:5121574
pubmed: 31687367
BMC Gastroenterol. 2021 Dec 19;21(1):482
pubmed: 34923965
Endocrine. 2021 Dec;74(3):538-545
pubmed: 34355342
J Clin Med. 2021 Dec 23;11(1):
pubmed: 35011784
BMJ Open. 2020 Nov 27;10(11):e039804
pubmed: 33247011
Diabetes Metab. 2022 Mar 23;48(4):101345
pubmed: 35339664
Lipids Health Dis. 2020 Oct 7;19(1):218
pubmed: 33028338
Curr Pharm Des. 2020;26(10):1079-1092
pubmed: 32003662
Hepatology. 2011 Sep 2;54(3):1082-1090
pubmed: 21618575
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Azizullah Beran (A)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Hazem Ayesh (H)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Mohammed Mhanna (M)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Waseem Wahood (W)

Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33314, USA.

Sami Ghazaleh (S)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Ziad Abuhelwa (Z)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Wasef Sayeh (W)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Nameer Aladamat (N)

Department of Neurology, University of Toledo, Toledo, OH 43606, USA.

Rami Musallam (R)

Department of Internal Medicine, St. Vincent Charity Medical Center, Cleveland, OH 44115, USA.

Reem Matar (R)

Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

Saif-Eddin Malhas (SE)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Ragheb Assaly (R)

Department of Internal Medicine, University of Toledo, Toledo, OH 43606, USA.

Classifications MeSH